Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference

Blood

Volumn 113, Issue 20, 2009, Pages 4829-4833

  Barosi, Giovanni ^a   Birgegard, Gunnar ^b   Finazzi, Guido ^c   Griesshammer, Martin ^d   Harrison, Claire ^e   Hasselbalch, Hans Carl ^f   Kiladjian, Jean Jacques ^g   Lengfelder, Eva ^h   McMullin, Mary Frances ⁱ   Passamonti, Francesco ^j   Reilly, John T ^k   Vannucchi, Alessandro M ^l   Barbui, Tiziano ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c OSPEDALI RIUNITI   (Italy)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITÉ PARIS 13   (France)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^j UNIVERSITY OF PAVIA   (Italy)

^k ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^l UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RETICULIN;

ALLELE; CONFERENCE PAPER; CONTROLLED STUDY; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; CONSENSUS; CONSENSUS DEVELOPMENT; EUROPE; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROGNOSIS; REMISSION;

CONSENSUS; EUROPE; HUMANS; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REMISSION INDUCTION; SOCIETIES, MEDICAL; THROMBOCYTHEMIA, ESSENTIAL;

EID: 66549086134     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-176818     Document Type: Conference Paper

References (29)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097. (Pubitemid 47281402)
2. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008:1299-1307.
3. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141-149.
4. + cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
5. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma. 2008;49:388-397. (Pubitemid 351298324)
6. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Haemost. 2007;33:321-329. (Pubitemid 46878104)
7. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis. 1998;24:9-13.
8. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997;34:51-54. (Pubitemid 27063142)
9. Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004; 101:2239-2246. (Pubitemid 39458679)
10. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005;90:261-262. (Pubitemid 40293293)
11. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN- alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110:2012-2018. (Pubitemid 350036861)
12. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90:1333-1338. (Pubitemid 41503648)
13. Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006;91:1281-1282. (Pubitemid 44408447)
14. Harrison CN, Campbell PJ, Buck G, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study: hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
15. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85:1011-1018. (Pubitemid 30831931)
16. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferonalpha. Cancer. 2006;107:451-458.
17. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065-3072.
18. White LJ, Ball JR. The clinical efficacy assessment project of the American College of Physicians. Int J Tech Assess Health Care. 1985;1:169-185.
19. William PL, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs. 1994;19:180-186.
20. Delbecq AL, van de Ven AH, Gustafson DH. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes. Glenview, IL: Scott, Foresman; 1975.
21. Thiele J, Kvasnicka HM. Myelofibrosis - what's in a name? Consensus on definition and EUMNET grading. Pathobiology. 2007;74:89-96. (Pubitemid 46985281)
22. Barosi G, Bordessoule D, Briere J, et al. European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005;106:2849-2853.
23. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232. (Pubitemid 38796497)
24. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-195. (Pubitemid 41602518)
25. Di Nisio M, Barbui T, Di Gennaro L, et al. The hematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249-259. (Pubitemid 46020752)
26. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1222. (Pubitemid 9071903)
27. Spivak JL. Erythropoietin use and abuse: when physiology and pharmacology collide. Adv Exp Med Biol. 2001;502:207-224.
28. Landolfi R, Marchioli R, Kutti J, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators: efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
29. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:1260-1261.